Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057330 · ClinicalTrials.gov registry record · Phase 3
HerpeVac Trial for Young Women
A Phase 3 study of Herpes Simplex Infection, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,323
- Enrollment target
- 20
- Study locations
NCT00057330 is a Phase 3 study of Herpes Simplex Infection that has completed, run by GlaxoSmithKline. The registered enrollment target is 8,323 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT00057330, a Phase 3 study of Herpes Simplex Infection, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,323 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to see if a herpes vaccine may prevent genital herpes disease in women who are not infected. The study will enroll approximately 7550 healthy women. These women will be randomly assigned to 1 of 2 possible study groups: herpes vaccine (experimental group) or hepatitis A vaccine (control group). Participants will receive their assigned vaccine at 0, 1, and 6 months. Participants will have 9 scheduled study visits and additional unscheduled visits for an evaluation of herpes if it is suspected. Participants will be involved in study related procedures for up to 20 months.
Conditions Studied
Interventions
- BIOLOGICAL HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine
- BIOLOGICAL Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine
Study Locations (20)
California
- GSK Investigational Site - Carson
- GSK Investigational Site - Long Beach
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Francisco
- GSK Investigational Site - Torrance
- GSK Investigational Site - Vallejo
Arizona
- GSK Investigational Site - Chandler
- GSK Investigational Site - Mesa
- GSK Investigational Site - Mesa
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Tempe
Georgia
- GSK Investigational Site - Athens
- GSK Investigational Site - Atlanta
- GSK Investigational Site - Augusta
- GSK Investigational Site - Satesboro
Alabama
- GSK Investigational Site - Birmingham
Colorado
- GSK Investigational Site - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,323 participants |
| Start Date | 2003-01-14 |
| Est. Completion | 2009-08-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057330
The ClinicalTrials.gov registry entry for NCT00057330 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8,323 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Herpes Simplex Infection appearing as the primary indexed condition, and to 2 interventions - of which HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine is the first listed.
NCT00057330 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Georgia.
Frequently Asked Questions
What is clinical trial NCT00057330 about?
NCT00057330 is a clinical study titled "HerpeVac Trial for Young Women". The primary purpose of this study is to see if a herpes vaccine may prevent genital herpes disease in women who are not infected. The study will enroll approximately 7550 healthy women. These women will be randomly assigned to 1 of 2 possible study groups: herpes vaccine (experimental group) or hepa...
What is the current status of trial NCT00057330?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,323 participants. The study started on 2003-01-14. Estimated completion is 2009-08-22.
What conditions does trial NCT00057330 study?
This clinical trial studies the following conditions: Herpes Simplex Infection.
What interventions are being tested in trial NCT00057330?
The interventions under investigation include: HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine (BIOLOGICAL), Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00057330?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00057330 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.